江苏隆达超合金股份有限公司 监事会关于 2023 年限制性股票激励计划首次授予部分 第一个归属期归属名单的核查意见 江苏隆达超合金股份有限公司（以下简称"公司"）监事会依据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上海证券交易 所科创板股票上市规则》（以下简称"《上市规则》"）等相关法律、法规、规章及规 范性文件和《江苏隆达超合金股份有限公司章程》（以下简称"《公司章程》"）的有 关规定，对公司《2023 年限制性股票激励计划（草案二次修订稿）》（以下简称"《激 励计划》"或"本激励计划"）首次授予部分第一个归属期归属名单进行审核，并发 表核查意见如下： 本次拟归属的激励对象符合《公司法》《证券法》等法律、法规和规范性文件 以及《公司章程》规定的任职资格，符合《管理办法》等法律、法规和规范性文件 规定的激励对象条件，符合公司本次激励计划规定的激励对象范围，其作为公司本 次激励计划激励对象的主体资格合法、有效，其获授的第二类限制性股票的归属条 件已成就。 综上所述，我们一致同意公司为本次 ...

江苏隆达超合金股份有限公司 第二届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 2025 年 6 月 13 日，江苏隆达超合金股份有限公司（以下简称"公司"）第二 届监事会第九次会议以现场结合通讯方式召开。会议通知已于 2025 年 6 月 7 日 通过电子邮件向全体监事发出。会议由监事会主席吕斌先生召集主持，会议应到 监事 3 人，实到监事 3 人，公司董事会秘书列席了会议，本次会议的召集、召开 和表决程序符合《中华人民共和国公司法》《江苏隆达超合金股份有限公司章程》 等相关法律法规的有关规定，会议决议合法有效。 证券代码：688231 证券简称：隆达股份 公告编号：2025-024 二、监事会会议审议情况 （一）审议通过了《关于调整 2023 年限制性股票激励计划授予价格及作废 部分已授予尚未归属的限制性股票的议案》 经核查，监事会认为：本次对公司《2023 年限制性股票激励计划（草案二 次修订稿）》（以下简称"《激励计划》"或"本次激励计划"）授予价格的调整符 合 ...

证券代码：688231 证券简称：隆达股份 公告编号：2025-023 二、董事会会议审议情况 经与会董事审议，逐项表决，形成决议如下： （一） 审议通过了《关于调整 2023 年限制性股票激励计划授予价格及作废 部分已授予尚未归属的限制性股票的议案》 鉴于公司 2023 年度、2024 年前三季度和 2024 年度权益分派方案已实施完 毕，根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、公司《2023 年限制性股票激励计划（草案二次修订稿）》（以下简称"《激励计划》"）的相关 规定，公司将限制性股票授予价格（含预留授予）由 12.08 元/股调整为 11.72 元 /股。 根据《管理办法》和公司《激励计划》的相关规定和公司 2023 年第二次临 时股东大会的授权，鉴于公司 2023 年限制性股票激励计划首次授予的激励对象 中 9 名激励对象已离职不再具备激励对象资格，其已获授但尚未归属的限制性股 票不得归属并由公司作废处理；1 名激励对象被选举为公司职工代表监事不再具 江苏隆达超合金股份有限公司 第二届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 ...

第二届董事会 2025 年第二次独立董事专门会议决议 江苏隆达超合金股份有限公司（以下简称"公司"）第二届董事会 2025 年第二 次独立董事专门会议于 2025 年 6 月 13 日在公司会议室以现场结合通讯方式召开。 本次会议由全体独立董事共同推举的陈建忠先生召集和主持，会议应出席独立董事 3 人，实际出席独立董事 3 人。本次会议的召集、召开和表决程序符合《上海证券 交易所科创板股票上市规则》《上市公司独立董事管理办法》等相关法律法规及规范 性文件和《江苏隆达超合金股份有限公司章程》（以下简称"《公司章程》"）的有关 规定，合法有效。 经全体独立董事表决，一致通过如下议案： 一、审议通过了《关于调整 2023 年限制性股票激励计划授予价格及作废部分已 授予尚未归属的限制性股票的议案》 经审阅，我们认为：本次对公司《2023 年限制性股票激励计划（草案二次修订 稿）》（以下简称"《激励计划》"或"本次激励计划"）授予价格的调整符合《公司章 程》《上市公司股权激励管理办法》（以下简称"《管理办法》"）等相关法律、法规、 规范性文件以及《激励计划》的相关规定，调整程序合法、合规。本次调整事项在 公司 2023 ...

国联民生证券承销保荐有限公司 关于江苏隆达超合金股份有限公司 差异化分红事项的核查意见 国联民生证券承销保荐有限公司（以下简称"国联民生保荐"或"保荐机构"） 作为江苏隆达超合金股份有限公司（以下简称"隆达股份"或"公司"）首次公开 发行股票并在科创板上市及进行持续督导的保荐机构，根据《证券发行上市保 荐业务管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等有关规定，对隆达股份 2024 年 度利润分配所涉及的差异化分红（以下简称"本次差异化分红"）相关事项进行 了审慎核查，具体情况如下： 一、本次差异化分红的原因 2024 年 3 月 18 日，公司召开第二届董事会第四次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用部分超募资 金通过上海证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人 民币普通股（A 股）股票。本次回购股份公司将在未来适宜时机全部用于股权 激励或员工持股计划。回购股份的价格不超过人民币 23.83 元/股（含），回购 资金总额不低于人民币 10,000.00 万元（含），不超过人民币 2 ...

国信证券股份有限公司（以下简称"国信证券"或"保荐机构"）作为江 苏隆达超合金股份有限公司（以下简称"隆达股份"或"公司"）首次公开发 行股票并在科创板上市及进行持续督导的保荐机构，根据《证券发行上市保荐 业务管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所上 市公司自律监管指引第 7 号——回购股份》等有关规定，对隆达股份 2024 年度 利润分配所涉及的差异化分红（以下简称"本次差异化分红"）相关事项进行 了审慎核查，具体情况如下： 一、本次差异化分红的原因 2024 年 3 月 18 日，公司召开第二届董事会第四次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用部分超募资 金通过上海证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人 民币普通股（A 股）股票。本次回购股份公司将在未来适宜时机全部用于股权 激励或员工持股计划。回购股份的价格不超过人民币 23.83 元/股（含），回购 资金总额不低于人民币 10,000.00 万元（含），不超过人民币 20,000.00 万元 （含），回购期限自董事会审议通过最终股份回购方案之日起 6 个月内。 关于江 ...

证券代码：688231 证券简称：隆达股份 公告编号：2025-022 江苏隆达超合金股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/10 | 2025/6/11 | 2025/6/11 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经江苏隆达超合金股份有限公司（以下简称"公司"）2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东， 江苏隆达超合金股份有限公司（以下简称"公司"）回购专用证券账户除外。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 是否涉及差异化分红送转：是 每股分配比例 每股现 ...

Core Viewpoint - Longda Co., Ltd. is intensifying its investment in overseas subsidiaries to advance its internationalization strategy, particularly through a $40 million increase in investment in its Singapore subsidiary, Singda Superalloy PTE. LTD. [1][5] Investment Strategy - Longda Co., Ltd. plans to invest an additional $40 million in its Singapore subsidiary to enhance overseas manufacturing capacity, upgrade equipment, and improve local operational systems [1][3] - The total investment in the Singapore subsidiary will rise from $20 million to $60 million following this additional investment [3] Financial Performance - As of the end of March, Longda Co., Ltd. had cash reserves of 175 million yuan (approximately $25 million) and discounted receivables of about 200 million yuan (approximately $29 million), which can be utilized for the increased investment [1][3] - In 2024, Longda Co., Ltd. reported overseas revenue of 262 million yuan (approximately $38 million), a year-on-year increase of 167.82% [7] - The company's gross margin for overseas markets reached 29.8%, an increase of 7.1 percentage points year-on-year [7] Market Expansion - The establishment of the Singapore subsidiary is part of Longda Co., Ltd.'s strategic development plan to create an international operational platform, including a business headquarters and R&D center in Southeast Asia [2] - The company is expanding its product lines to include corrosion-resistant alloys and high-performance special deformation alloys to meet international customer demands [3] Recent Developments - Longda Co., Ltd. has completed the acquisition of land for its Malaysian subsidiary, which is set to begin construction in July 2025 [2][4] - The company has seen a recovery in its performance, with 2024 revenues reaching 1.391 billion yuan (approximately $200 million), a 15.22% increase year-on-year, and a net profit of 66.11 million yuan (approximately $9.5 million), up 19.38% [6][8]

Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]

Core Viewpoint - The company, Jiangsu Longda Superalloy Co., Ltd., is increasing its investment in its wholly-owned subsidiary in Singapore, Singda Superalloy Pte. Ltd., by $40 million to enhance its overseas manufacturing capacity and product offerings [1][4]. Investment Overview - The total investment in the Singapore subsidiary will rise from $20 million to $60 million following this additional investment [4]. - The additional $40 million will be allocated for expanding factory infrastructure, upgrading key production and testing equipment, supplementing operational funds, and improving the local supply chain [4]. Project Development - The Singapore subsidiary has established a wholly-owned subsidiary in Malaysia, Singda Superalloy (Malaysia) Sdn. Bhd., which is set to begin construction in July 2025 with a projected construction period of 15 months [3]. - The project will include the production of high-temperature alloy master alloys, corrosion-resistant nickel-based alloys, and other specialized alloys [3]. Financial Position - As of the end of the first quarter of 2025, the company reported cash and cash equivalents of approximately 175 million yuan (about $25 million) available for this investment [4]. - The company has also secured a total bank credit line of 120 million yuan (approximately $17 million) to support its operational needs [4]. Decision-Making Process - The investment decision was approved by the company's board of directors with unanimous support, and it does not require shareholder approval as it falls within the board's authority [5].